Intestine Segment, by Type to Account Larger Share in Organoids Services Market during 2023-2031

According to our new research study on "Organoids Services Market Forecast to 2031 - Global Analysis - by Type, Application, Source, and Geography," the market was valued at US$ 3.03 billion in 2023 and is projected to reach US$ 15.01 billion by 2031; it is expected to register a CAGR of 22.3% during 2023-2031. Factors contributing to the organoids services market growth include the rising demand for novel drug screening services, and an upsurge in the popularity of customized medications. However, the dearth of skilled professionals and stringent safety regulations hamper the market growth.

Organoids are emerging as a powerful asset for researchers and drug developers as they seek more efficient and accurate methods to identify promising drug candidates and predict their efficacy. The ability to generate patient-derived organoids opens up exciting possibilities for personalized drug screening. Organoids serve as realistic and relevant models for drug screening compared to traditional 2D cell cultures. They mimic the complexity of human organs, including their cellular composition, structure, and function, providing a more accurate representation of drug responses in the human body. This enables researchers to identify potential drug candidates more confidently and avoid costly and time-consuming failures in clinical trials. The organoid services market is experiencing rapid growth owing to the increasing demand for innovative screening services.

By creating organoids from a patient's cells, researchers can tailor drug testing to individual responses, improving the likelihood of treatment success through a personalized approach. The integration of advanced technologies, such as high-throughput screening platforms and automated image analysis, further enhances the capabilities of organoid screening services. With the integration of high-throughput screening and organoids, researchers can test many drug compounds efficiently, analyze results more accurately, and accelerate the drug discovery process. Thus, the global focus on innovative screening services, driven by the popularity of personalized medicine and the need for faster drug development, favors the growth of the organoids services market. In January 2024, HUB Organoids (HUB) launched IntegriGut Screen for the global market. This innovative screening service employs patient-derived organoid (PDO) Monolayers--organoid monolayers derived from inflammatory bowel disease (IBD) patients-allowing access to high-quality human data on epithelial barrier function and accelerating the development of novel IBD therapies.

Based on type, the organoids services market is classified into intestine, liver, stomach, pancreas, lung, brain, kidney, and others. The intestine segment held the largest share of the market in 2023, and it is further anticipated to register the highest CAGR during the forecast period.

By application, the market is segmented into developmental biology, infectious disease pathology, regenerative medicine, drug toxicity & efficacy testing, drug discovery & personalized medicine, and others. The developmental biology disease segment held the largest share of the market in 2023; it is further anticipated to register the highest CAGR during 2023-2031.

Based on source, the organoids services market is divided into pluripotent stem cells and organ-specific adult stem cells. The pluripotent stem cells segment held a larger share of the market in 2023. The pluripotent stem cells segment is anticipated to register a higher CAGR during the forecast period.

Sino Biological Inc.; Eurofins Scientific SE; Molecular Devices, LLC.; InSphero; Cyprio; InnoSer; LABTOO; CUSABIO TECHNOLOGY LLC; Oncodesign Services; and HUB Organoids B.V. (Hubrecht Organoid Technology) are among the leading companies operating in the global organoids services market.

Companies operating in the organoids services market adopt various organic and inorganic strategies. Organic strategies mainly include product launches and product approvals. Acquisitions, collaborations, and partnerships are among the inorganic growth strategies witnessed in the organoids services market. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall organoids services market growth. Further, acquisition and partnership strategies help them strengthen their customer base and expand their product portfolios.



Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com